SLC5A2 and type 2 diabetes mellitus: Canagliflozin, dapagliflozin, and empagliflozin, three sodium-glucose cotransporter 2 (SGLT2) inhibitors have been approved for the treatment of T2DM by promoting urinary glucose excretion in an insulin-independent manner (9–12).